BUSINESS● LOWSep 25 · Sep 25, 2026, 11:00 AM
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
CNBC · global
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESSnowLamu Refinery: Is Kenya ready to grant a fuel monopoly to Aliko Dangote?Jeune AfriqueBUSINESS34m agoJust Eat apologises after AI-generated images blunderAl Jazeera [en]